Table 3. Demographic information and clinical characteristics in PD patients at baseline.
| Variable | PD without cognitive decline (N=15) | PD with cognitive decline (N=13) | Statistic (χ2/t/Z) | P value |
|---|---|---|---|---|
| Gender (male/female)a | 6/9 | 5/8 | – | 1.000 |
| Age (year)b | 57.60±11.10 | 61.23±11.27 | −0.857 | 0.399 |
| Education (year)b | 8.53±3.68 | 9.53±4.99 | −0.612 | 0.546 |
| MMSEc | 27.66±2.41 | 28.92±1.49 | −1.153 | 0.249 |
| MoCAc | 26.00±1.19 | 26.76±1.73 | −1.667 | 0.096 |
| Disease duration (year) c | 4.75±3.09 | 4.06±2.22 | −0.741 | 0.459 |
| UPDRS-III scoreb | 15.33±4.45 | 16.78±6.77 | −0.677 | 0.505 |
| Levodopa dosage (mg/day) b | 308.82±59.12 | 314.49±52.91 | −0.266 | 0.793 |
a, the P value for gender distribution in the two groups was calculated using Fisher exact test. b, the P value was calculate using two-tail two-sample t-test. c, the P value was calculate using two-tail Mann-Whitney U test. MMSE, Mini Mental State Examination; MoCA, Montreal Cognitive Assessment; PD, Parkinson’s disease.